24
Participants
Start Date
May 21, 2020
Primary Completion Date
February 1, 2024
Study Completion Date
February 1, 2024
CC-97540
"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection."
Local Institution - 001, New York
Local Institution - 008, New York
Local Institution - 010, Charlotte
Local Institution - 004, Atlanta
Nebraska Medicine Fred and Pamela Buffett Cancer Center, Omaha
Huntsman Cancer Institute - University of Utah, Salt Lake City
Oregon Health and Science University OHSU, Portland
Local Institution - 003, Birmingham
Local Institution - 011, Boston
Beth Israel Deaconess Medical Center, Boston
Hackensack University Medical Center, Hackensack
Foothills Medical Centre - Tom Baker Cancer Centre, Calgary
Vancouver General Hospital, Vancouver
Juravinski Cancer Centre, Hamilton
Juno Therapeutics, a Subsidiary of Celgene
INDUSTRY